Home › Melanoom › Massachusetts › Boston
Melanoom klinische studies in Boston, MA
26 studies voor Melanoom zoeken deelnemers op locaties in en rond Boston (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekruterenFase 1/2
- Tufts Medical Center, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
RekruterenFase 2
- Local Institution - 0124, Boston
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
RekruterenFase 1/2
- Massachusetts General Hospital Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
RekruterenFase 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RekruterenFase 1/2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Cryoablation+Ipilimumab+Nivolumab in Melanoma
RekruterenFase 2
- Massachusetts General Hospital Cancer Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruterenFase 1/2
- Dana-Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
RekruterenObservatieonderzoek
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekruterenFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RekruterenFase 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
RekruterenFase 1/2
- Call for Information (Investigational Site 0026), Boston
Video Education With Result Dependent dIsclosure
Rekruteren
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RekruterenFase 1/2
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RekruterenFase 3
- Massachusetts General Hospital, Boston
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
RekruterenFase 2/3
- Dana Farber, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RekruterenFase 2/3
- Massachusetts General Hospital, Boston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
RekruterenFase 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203 Combined With mRNA-4203
RekruterenFase 1
- Dana Farber Cancer Institute, Boston
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
RekruterenFase 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
RekruterenFase 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
RekruterenFase 2
- Dana Farber Cancer Institute, Boston
Melanoom studies in andere steden
- Houston, TX59 studies
- New York City, NY38 studies
- Los Angeles, CA34 studies
- Nashville, TN33 studies
- Pittsburgh, PA31 studies
- Philadelphia, PA23 studies
- San Francisco, CA22 studies
- Durham, NC21 studies
- Atlanta, GA21 studies
- St. Louis, MO21 studies
- Salt Lake City, UT21 studies
- Columbus, OH21 studies
Andere studies in Boston
- Borstkanker111 studies
- Niet-kleincellige longkanker90 studies
- Kanker (alle vormen)86 studies
- Colorectale kanker63 studies
- Metastatische kanker63 studies
- Longkanker62 studies
- Eierstokkanker61 studies
- Prostaatkanker59 studies
- Depressie52 studies
- Endometriumkanker50 studies
- Hartfalen44 studies
- Acute myeloïde leukemie44 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.